EP4059964A1
(en)
*
|
2007-04-03 |
2022-09-21 |
Amgen Research (Munich) GmbH |
Cross-species-specific binding domain
|
US10981998B2
(en)
*
|
2008-10-01 |
2021-04-20 |
Amgen Research (Munich) Gmbh |
Cross-species-specific single domain bispecific single chain antibody
|
CA2738565C
(en)
*
|
2008-10-01 |
2023-10-10 |
Micromet Ag |
Cross-species-specific psmaxcd3 bispecific single chain antibody
|
CN102714296A
(zh)
|
2009-05-19 |
2012-10-03 |
Aic布莱博公司 |
复合集电器及形成其的方法
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
TWI653333B
(zh)
|
2010-04-01 |
2019-03-11 |
安進研究(慕尼黑)有限責任公司 |
跨物種專一性之PSMAxCD3雙專一性單鏈抗體
|
DK3029066T3
(da)
|
2010-07-29 |
2019-05-20 |
Xencor Inc |
Antistoffer med modificerede isoelektriske punkter
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
SG194510A1
(en)
*
|
2011-04-22 |
2013-12-30 |
Emergent Product Dev Seattle |
Prostate-specific membrane antigen binding proteins and related compositionsand methods
|
CN103842383B
(zh)
*
|
2011-05-16 |
2017-11-03 |
健能隆医药技术(上海)有限公司 |
多特异性fab融合蛋白及其使用方法
|
EP2747781B1
(en)
*
|
2011-08-23 |
2017-11-15 |
Roche Glycart AG |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
WO2013128027A1
(en)
*
|
2012-03-01 |
2013-09-06 |
Amgen Research (Munich) Gmbh |
Long life polypeptide binding molecules
|
US20140004121A1
(en)
|
2012-06-27 |
2014-01-02 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
EP2900696A1
(en)
*
|
2012-09-25 |
2015-08-05 |
Glenmark Pharmaceuticals S.A. |
Purification of hetero-dimeric immunoglobulins
|
KR20150082328A
(ko)
*
|
2012-11-06 |
2015-07-15 |
바이엘 파마 악티엔게젤샤프트 |
이중특이성 t-세포 연계체(bites)의 제제
|
CN103087171B
(zh)
*
|
2012-12-24 |
2015-01-14 |
中国人民解放军第四军医大学 |
一种用于前列腺癌早期诊断和治疗的抗psma/fitc双特异性抗体及其制备方法
|
WO2014110601A1
(en)
|
2013-01-14 |
2014-07-17 |
Xencor, Inc. |
Novel heterodimeric proteins
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US9738722B2
(en)
|
2013-01-15 |
2017-08-22 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
ES2829499T3
(es)
|
2013-02-05 |
2021-06-01 |
Engmab Sarl |
Método para la selección de anticuerpos contra BCMA
|
EP2762497A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
JO3529B1
(ar)
*
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
EP3424952A1
(en)
*
|
2013-03-15 |
2019-01-09 |
Amgen, Inc |
Heterodimeric bispecific antibodies
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
US9695245B2
(en)
|
2013-03-15 |
2017-07-04 |
Edimer Pharmaceuticals, Inc |
Anti-ectodysplasin antibodies
|
EP2970446A1
(en)
|
2013-03-15 |
2016-01-20 |
Amgen Research (Munich) GmbH |
Antibody constructs for influenza m2 and cd3
|
EP3421495A3
(en)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
EP2789630A1
(en)
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
ES2683268T3
(es)
|
2013-07-25 |
2018-09-25 |
Cytomx Therapeutics, Inc. |
Anticuerpos multiespecíficos, anticuerpos activables multiespecíficos y métodos para usar los mismos
|
CR20160506A
(es)
|
2014-03-28 |
2017-03-10 |
Xencor Inc |
Anticuerpos biespecíficos que se unen a cd38 y cd3
|
JP2017520575A
(ja)
|
2014-07-01 |
2017-07-27 |
ファイザー・インク |
二重特異的ヘテロ二量体ダイアボディおよびその使用
|
US9212225B1
(en)
*
|
2014-07-01 |
2015-12-15 |
Amphivena Therapeutics, Inc. |
Bispecific CD33 and CD3 binding proteins
|
US10669337B2
(en)
*
|
2014-07-25 |
2020-06-02 |
Cytomx Therapeutics, Inc. |
Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
|
DK3223845T3
(da)
|
2014-11-26 |
2021-08-16 |
Xencor Inc |
Heterodimere antistoffer, der binder cd3 og cd20
|
CA2968878A1
(en)
|
2014-11-26 |
2016-06-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
CN114230667A
(zh)
|
2015-01-23 |
2022-03-25 |
赛诺菲 |
抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
|
EP3256495A4
(en)
*
|
2015-02-11 |
2018-09-19 |
Aptevo Research and Development LLC |
Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
KR101997241B1
(ko)
|
2015-05-21 |
2019-07-09 |
하푼 테라퓨틱스, 인크. |
삼중특이성 결합 단백질 및 사용 방법
|
CN108289949B
(zh)
*
|
2015-05-29 |
2022-04-12 |
安普希韦纳治疗公司 |
双特异性cd33和cd3结合蛋白质的使用方法
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
JOP20160154B1
(ar)
*
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
US10683369B2
(en)
|
2015-08-03 |
2020-06-16 |
Engmab Sàrl |
Monoclonal antibodies against BCMA
|
DK3337824T3
(da)
|
2015-08-17 |
2020-08-24 |
Janssen Pharmaceutica Nv |
Anti-bcma-antistoffer, bispecifikke antigen-bindende molekyler, som binder bcma og cd3, og anvendelse deraf
|
IL307276A
(en)
|
2015-08-28 |
2023-11-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
JP7002446B2
(ja)
|
2015-09-21 |
2022-03-04 |
アプティーボ リサーチ アンド デベロップメント エルエルシー |
Cd3結合ポリペプチド
|
CN105198992B
(zh)
*
|
2015-10-16 |
2018-07-13 |
中国人民解放军海军总医院 |
一种人源抗创伤弧菌溶血素蛋白(vvh)抗体的制备方法与应用
|
MA43164A
(fr)
|
2015-11-02 |
2018-09-12 |
Janssen Pharmaceutica Nv |
Anticorps anti-il1rap, molécules bispécifiques de liaison à un antigène liant il1rap et cd3 et leurs utilisations
|
CN108699136B
(zh)
*
|
2015-12-07 |
2022-03-18 |
Xencor股份有限公司 |
结合cd3和psma的异二聚抗体
|
EP3411404B1
(en)
*
|
2016-02-03 |
2022-11-09 |
Amgen Research (Munich) GmbH |
Psma and cd3 bispecific t cell engaging antibody constructs
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
CN109476756B
(zh)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
一种多特异性Fab融合蛋白及其用途
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
BR112018073739A2
(pt)
|
2016-05-20 |
2019-02-26 |
Harpoon Therapeutics, Inc. |
proteína de ligação de albumina sérica de domínio único
|
WO2017218707A2
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
CN109641049B
(zh)
|
2016-06-21 |
2023-07-07 |
特尼奥生物股份有限公司 |
Cd3结合抗体
|
CN116063545A
(zh)
|
2016-06-28 |
2023-05-05 |
Xencor股份有限公司 |
结合生长抑素受体2的异源二聚抗体
|
TWI781108B
(zh)
|
2016-07-20 |
2022-10-21 |
比利時商健生藥品公司 |
抗gprc5d抗體、結合gprc5d與cd3之雙特異性抗原結合分子及其用途
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
BR112019004873A2
(pt)
*
|
2016-09-14 |
2019-06-11 |
Teneobio Inc |
anticorpos de ligação a cd3
|
BR112019005333A2
(pt)
*
|
2016-09-21 |
2019-06-11 |
Aptevo Research And Development Llc |
proteínas de ligação a cd123 e composições e métodos relacionados
|
EP3526241A1
(en)
|
2016-10-14 |
2019-08-21 |
Xencor, Inc. |
Il15/il15r heterodimeric fc-fusion proteins
|
CN110167964B
(zh)
|
2016-11-02 |
2023-12-01 |
百时美施贵宝公司 |
组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
|
MX2019006045A
(es)
|
2016-11-23 |
2019-11-11 |
Harpoon Therapeutics Inc |
Proteinas triespecificas dirigidas a psma y metodos de uso.
|
KR102275008B1
(ko)
|
2016-11-23 |
2021-07-13 |
하푼 테라퓨틱스, 인크. |
전립선 특이 막 항원 결합 단백질
|
AU2017382251A1
(en)
|
2016-12-21 |
2019-07-11 |
Teneobio, Inc. |
Anti-BCMA heavy chain-only antibodies
|
EP3589662A4
(en)
|
2017-02-28 |
2020-12-30 |
Harpoon Therapeutics, Inc. |
INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN
|
TWI710637B
(zh)
*
|
2017-03-29 |
2020-11-21 |
臺北醫學大學 |
具抗原專一性的t細胞及其用途
|
US10543271B2
(en)
|
2017-05-12 |
2020-01-28 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
CN117567624A
(zh)
|
2017-06-20 |
2024-02-20 |
特纳奥尼股份有限公司 |
仅有重链的抗bcma抗体
|
WO2018237148A1
(en)
|
2017-06-21 |
2018-12-27 |
Gilead Sciences, Inc. |
MULTISPECIFIC ANTIBODIES TARGETING HIV GP120 AND CD3
|
CN111132733A
(zh)
|
2017-06-30 |
2020-05-08 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白
|
HUE058233T2
(hu)
|
2017-08-03 |
2022-07-28 |
Amgen Inc |
Interleukin-21-muteinek és kezelési eljárások
|
SG11202001499WA
(en)
|
2017-09-08 |
2020-03-30 |
Amgen Inc |
Inhibitors of kras g12c and methods of using the same
|
US11136403B2
(en)
|
2017-10-13 |
2021-10-05 |
Harpoon Therapeutics, Inc. |
Trispecific proteins and methods of use
|
EP3694871A4
(en)
|
2017-10-13 |
2021-11-10 |
Harpoon Therapeutics, Inc. |
B-CELL MATURATION ANTIG-BINDING PROTEINS
|
AU2018347607A1
(en)
|
2017-10-14 |
2020-03-26 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
US11312770B2
(en)
|
2017-11-08 |
2022-04-26 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
US10426424B2
(en)
|
2017-11-21 |
2019-10-01 |
General Electric Company |
System and method for generating and performing imaging protocol simulations
|
CA3086199A1
(en)
|
2017-12-19 |
2019-06-27 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
US11873336B2
(en)
|
2017-12-22 |
2024-01-16 |
Teneobio, Inc. |
Heavy chain antibodies binding to CD22
|
UY38041A
(es)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
CR20200330A
(es)
|
2018-01-12 |
2020-12-23 |
Amgen Inc |
Anticuerpos anti-pd-1 y métodos de tratamiento
|
US10982006B2
(en)
|
2018-04-04 |
2021-04-20 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
KR20210010862A
(ko)
|
2018-04-18 |
2021-01-28 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도
|
WO2019204655A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
JOP20190116A1
(ar)
|
2018-05-24 |
2019-11-24 |
Janssen Biotech Inc |
الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
|
EP3802609A2
(en)
|
2018-05-24 |
2021-04-14 |
Janssen Biotech, Inc. |
Psma binding agents and uses thereof
|
PE20210320A1
(es)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas
|
CN112566938A
(zh)
|
2018-06-03 |
2021-03-26 |
拉姆卡普生物测试有限公司 |
针对ceacam5和cd47的双特异性抗体
|
JP7425049B2
(ja)
|
2018-09-25 |
2024-01-30 |
ハープーン セラピューティクス,インク. |
Dll3結合タンパク質および使用方法
|
JP2022503959A
(ja)
|
2018-10-03 |
2022-01-12 |
ゼンコア インコーポレイテッド |
Il-12ヘテロ二量体fc-融合タンパク質
|
EP3930850A1
(en)
|
2019-03-01 |
2022-01-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
CA3136892A1
(en)
*
|
2019-04-19 |
2020-10-22 |
Janssen Biotech, Inc. |
Methods of treating renal cancer with an anti- psma/cd3 antibody
|
AR118720A1
(es)
*
|
2019-04-19 |
2021-10-27 |
Janssen Biotech Inc |
Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
|
CN114206927A
(zh)
|
2019-06-14 |
2022-03-18 |
特尼奥生物股份有限公司 |
与cd22和cd3结合的多特异性重链抗体
|
WO2021006199A1
(ja)
|
2019-07-05 |
2021-01-14 |
小野薬品工業株式会社 |
Pd-1/cd3二重特異性タンパク質による血液がん治療
|
JP2022548947A
(ja)
|
2019-09-18 |
2022-11-22 |
ランカプ バイオ アルファ アーゲー |
Ceacam5およびcd3に対する二特異性抗体
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
EP3842461A1
(en)
*
|
2019-12-23 |
2021-06-30 |
Albert-Ludwigs-Universität Freiburg |
Chimeric antigen receptors that bind to prostate specific membrane antigen
|
CA3164385A1
(en)
|
2020-01-13 |
2021-07-22 |
Aptevo Research And Development Llc |
Formulations for protein therapeutics
|
KR20220140500A
(ko)
|
2020-01-13 |
2022-10-18 |
압테보 리서치 앤드 디벨롭먼트 엘엘씨 |
약물 전달 시스템 성분에 대한 치료제 단백질의 흡착을 방지하기 위한 방법 및 조성물
|
EP4106806A1
(en)
|
2020-02-21 |
2022-12-28 |
Harpoon Therapeutics, Inc. |
Flt3 binding proteins and methods of use
|
JP2023526774A
(ja)
|
2020-04-29 |
2023-06-23 |
テネオバイオ, インコーポレイテッド |
重鎖定常領域が修飾された多重特異性重鎖抗体
|
AU2021272291A1
(en)
|
2020-05-11 |
2023-02-02 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
AU2021329378A1
(en)
|
2020-08-19 |
2023-03-23 |
Xencor, Inc. |
Anti-CD28 compositions
|
WO2022060878A1
(en)
|
2020-09-16 |
2022-03-24 |
Amgen Inc. |
Methods for treating prostate cancer
|
AU2021345124A1
(en)
|
2020-09-16 |
2023-03-30 |
Amgen Inc. |
Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
|
WO2022081822A1
(en)
*
|
2020-10-15 |
2022-04-21 |
Janux Therapeutics, Inc. |
Antibodies targeting psma and cd3 and uses thereof
|
AU2021374036A1
(en)
*
|
2020-11-06 |
2023-06-08 |
Amgen Inc. |
Polypeptide constructs selectively binding to cldn6 and cd3
|
EP4240768A2
(en)
|
2020-11-06 |
2023-09-13 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
TW202237654A
(zh)
|
2020-12-09 |
2022-10-01 |
美商詹努克斯治療有限公司 |
與經腫瘤活化之靶定psma及效應細胞抗原之抗體相關之組合物及方法
|
JP2024507180A
(ja)
|
2021-02-16 |
2024-02-16 |
ヤンセン ファーマシューティカ エヌ.ベー. |
Bcma、gprc5d、及びcd3を標的とする三重特異的抗体
|
CN117157319A
(zh)
|
2021-03-09 |
2023-12-01 |
Xencor股份有限公司 |
结合cd3和cldn6的异二聚抗体
|
WO2022192586A1
(en)
|
2021-03-10 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
BR112023019484A2
(pt)
|
2021-03-24 |
2023-12-05 |
Janssen Biotech Inc |
Anticorpo triespecífico que tem como alvo cd79b, cd20 e cd3
|
WO2022232376A1
(en)
|
2021-04-29 |
2022-11-03 |
Amgen Inc. |
Methods for reducing low molecular weight species of recombinantly-produced proteins
|
CN117279947A
(zh)
|
2021-05-06 |
2023-12-22 |
安进研发(慕尼黑)股份有限公司 |
用于在增殖性疾病中使用的靶向cd20和cd22的抗原结合分子
|
WO2022246244A1
(en)
|
2021-05-21 |
2022-11-24 |
Aptevo Research And Development Llc |
Dosing regimens for protein therapeutics
|
CN115536740A
(zh)
*
|
2021-06-30 |
2022-12-30 |
苏州方德门达新药开发有限公司 |
介导细胞内有效滞留cd3的空间构象表位及其应用
|
WO2023183231A1
(en)
|
2022-03-21 |
2023-09-28 |
Amgen Inc. |
Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer
|
TW202346368A
(zh)
|
2022-05-12 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
|